Manila lifts curbs on AstraZeneca shots
April 20 2021 12:28 AM
AstraZeneca Covid-19 vaccine
AstraZeneca Covid-19 vaccine

AFP/ Manila

The Philippines has lifted a suspension on the AstraZeneca Covid-19 vaccine for people under 60, an official said yesterday, arguing “the benefits outweigh the risk” as the country battles record infections.
Several countries suspended use of the drug after it was linked to rare but serious blood clotting.
Most have subsequently resumed after the European Medicines Agency, emphasised the benefits of the jab, judging it “safe and effective”. Philippine health undersecretary Rosario Vergeire said the drug regulator had recommended “extra precautions” for administering the shot to people with certain existing health conditions. “We need to recall that only a very small percentage of the population is affected by adverse effects from AstraZeneca,” Vergeire told reporters.
“We will come up with guidelines on the use of AstraZeneca to include these different precautions that was stated by the Food and Drug Administration.”
The Philippines has received around 3mn doses of Covid-19 vaccines so far — the vast majority from China’s Sinovac.
It also got 525,600 AstraZeneca doses through the Covax programme, according to official data.
The country expects another 3mn AstraZeneca doses in the coming months.
More than 1.2mn people have received their first dose of a vaccine, most of them health workers, official data shows.
Fewer than 200,000 people are fully vaccinated seven weeks after inoculations started.
President Rodrigo Duterte’s government has been skewered by critics over its handling of the pandemic and efforts to secure vaccines. A lockdown in the capital and four surrounding provinces has been in place for the past three weeks in a bid to curb the spread of the virus and decongest hospitals.
The roughly 3mn vaccine doses received so far represent a fraction of the shots Manila has been negotiating with seven manufacturers to secure.

There are no comments.

LEAVE A COMMENT Your email address will not be published. Required fields are marked*